HIGHLIGHTS
- who: Makito Miyake and collaborators from the Department of Urology, Nara Medical University, Shijo, Kashihara, Nara, Japan have published the research work: Case Report Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule- Disrupting Agent, in the Journal: Case Reports in Urology of 14/01/2023
- what: This case report suggests that a tumor response to EV can be expected in taxane-refractory aUC.
SUMMARY
Platinum-based chemotherapy, immune checkpoint inhibitors, taxane-based chemotherapy, and FGFR-targeted therapy are currently available for patients with aUC. Evaluation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.